

10/512699

10/590707 Y = direct bond

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS EXPRESS	19	SEPTEMBER 2007	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

<12/04/2007>

Erich Leese

10/513699

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:54:18 ON 19 SEP 2007

=>

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.46

5.46

FILE 'REGISTRY' ENTERED AT 14:09:32 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707.str


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

10/513699



G1 H, NH2, Cb, Ak

G2 C, H, Ak

G3 C, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:10:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4898 TO ITERATE

100.0% PROCESSED 4898 ITERATIONS

152 ANSWERS

SEARCH TIME: 00.00.01

L2 152 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

178.01

FILE 'CAPLUS' ENTERED AT 14:10:41 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

<12/04/2007>

Erich Leese

10/513699

=> s l2 full

L3 3 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:729635 CAPLUS

DOCUMENT NUMBER: 147:72778

TITLE: Preparation of quinazolinone derivatives and related analogs as antiproliferative agents

INVENTOR(S): Bergnes, Gustave

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 54pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018058	A2	20040304	WO 2003-US26093	20030820
WO 2004018058	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003262747	A1	20040311	AU 2003-262747	20030820
EP 1539180	A2	20050615	EP 2003-793179	20030820
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005536553	T	20051202	JP 2004-531141	20030820
PRIORITY APPLN. INFO.:			US 2002-404864P	P 20020821
			WO 2003-US26093	W 20030820
OTHER SOURCE(S):	MARPAT 147:72778			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-4 independently = H, OH, (un)substituted alkyl, etc.; R5 = H, (un)substituted alkyl, aryl, or aralkyl; R6 and R9 independently = H, (un)substituted alkyl, aryl, etc.; R7 = (un)substituted alkyl, aryl or aralkyl; R8 = H, (un)substituted alkyl, aryl or aralkyl; n = 1 or 2], and their pharmaceutically acceptable salts, are prepared and disclosed as antiproliferative agents by modulation of KSP (a mitotic kinesin) activity. Thus, e.g., II was prepared by substitution of 3-benzyl-2-(1-bromopropyl)-7-chloro-3H-quinazolin-4-one with 3-p-tolylpiperazine-1-carboxylic acid tert-Bu ester. Bioassays are described and the compds. of the invention were stated to show activity.

10/513699


IT 941712-02-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolone derivs. and related analogs as antiproliferative agents)

RN 941712-02-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[1-[4-[4-(1-methylethyl)-2-pyridinyl]-1-piperazinyl]propyl]-3-(phenylmethyl)- (CA INDEX NAME)



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:979639 CAPLUS

DOCUMENT NUMBER: 143:286443

TITLE: Preparation of pyrimidine derivatives as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A

INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan

SOURCE: PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005217320	A1	20050909	AU 2005-217320	20050225
CA 2557541	A1	20050909	CA 2005-2557541	20050225
EP 1724267	A1	20061122	EP 2005-719969	20050225
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			



<12/04/2007>

Erich Leese

10/513699

CN 1922171	A	20070228	CN 2005-80005603	20050225
US 2007197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040	A 20040226
			JP 2004-322858	A 20041105
			WO 2005-JP3691	W 20050225

OTHER SOURCE(S): MARPAT 143:286443
GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT3 receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.


IT 864386-59-4P 864386-62-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864386-59-4 CAPLUS


CN Spiro[1,3-dioxolane-2,6'-(5'H)-quinazolin]-4'-(3'H)-one,
3'-amino-7',8'-dihydro-2'-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI)
(CA INDEX NAME)

10/513599



RN 864386-62-9 CAPLUS

CN 4,6-Quinazolinedione, 3-amino-3,5,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



IT 864385-95-5P 864385-96-6P 864385-97-7P
864385-98-8P 864385-99-9P 864386-00-5P
864386-01-6P 864386-02-7P 864386-03-8P
864386-04-9P 864386-05-0P 864386-06-1P
864386-07-2P 864386-08-3P 864386-09-4P
864386-10-7P 864386-11-8P 864386-13-0P
864386-14-1P 864386-15-2P 864386-16-3P
864386-18-5P 864386-19-6P 864386-20-9P
864386-21-0P 864386-22-1P 864386-23-2P
864386-25-4P 864386-26-5P 864386-27-6P
864386-28-7P 864386-30-1P 864386-31-2P
864386-32-3P 864386-34-5P 864386-35-6P
864386-37-8P 864386-38-9P 864386-39-0P
864386-40-3P 864386-41-4P 864386-45-8P
864386-46-9P 864386-47-0P 864386-49-2P
864386-50-5P 864386-52-7P 864386-53-8P
864386-54-9P 864386-55-0P 864386-56-1P
864386-57-2P 864386-58-3P 864386-63-0P
864386-64-1P 864386-76-5P 864386-77-6P
864386-78-7P 864386-79-8P 864386-80-1P
864386-81-2P 864386-82-3P 864386-83-4P
864386-84-5P 864386-85-6P 864386-86-7P
864386-87-8P 864386-88-9P 864386-89-0P
864386-90-3P 864386-91-4P 864386-92-5P
864386-93-6P 864386-95-8P 864386-96-9P
864386-97-0P 864386-99-2P 864387-00-8P
864387-01-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

10/513699


RN 864385-95-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864385-96-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864385-97-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864385-98-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864385-99-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(3-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-00-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(3,4-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-01-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2,3-dihydro-1H-cyclopenta[c]quinolin-4-yl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-02-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(7,8,9,10-tetrahydro-6-phenanthridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-03-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(3,4-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-04-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2,3-dihydro-1H-cyclopenta[c]quinolin-4-yl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-05-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(7,8,9,10-tetrahydro-6-phenanthridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-06-1 CAPLUS

CN Pyrido[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-07-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 864386-08-3 CAPLUS


CN Pyrido[3,2-d]pyrimidin-4(3H)-one, 3-amino-2-[4-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 864386-09-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-7-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-10-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-bromo-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-11-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6,7,8-trimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-13-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-14-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-15-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-16-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(5-methoxy-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-18-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-8-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-19-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-20-9 CAPLUS

CN Benzo[g]quinazolin-4(3H)-one, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (CA INDEX NAME)




RN 864386-21-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-8-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (CA INDEX NAME)



RN 864386-22-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5-hydrazino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (9CI) (CA INDEX NAME)



RN 864386-23-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-7-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (CA INDEX NAME)

10/513699




RN 864386-25-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(5-methoxy-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-26-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-phenyl-2-[4-[4-(2-methoxyquinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-27-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4,8-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-28-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4,8-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-30-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-31-2 CAPLUS

CN Benzo[g]quinazolin-4(3H)-one, 3-amino-5,5a,6,7,8,9,9a,10-octahydro-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-32-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-5,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-34-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-8-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-35-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6,7-dimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-37-8 CAPLUS

CN 5,8-Imino-4H-cycloheptapyrimidin-4-one, 3-amino-3,5,6,7,8,9-hexahydro-10-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 864386-38-9 CAPLUS


CN Pyrido[4,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-39-0 CAPLUS


10/513699

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)




RN 864386-40-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[2-[4-(2-quinolinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 864386-41-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[5-[4-(2-quinolinyl)-1-piperazinyl]pentyl]- (CA INDEX NAME)



RN 864386-45-8 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-6-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-46-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-47-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-7-(trifluoromethyl)- (CA INDEX NAME)




RN 864386-49-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-50-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-7-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-52-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-7-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-53-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-54-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-ethyl-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-55-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-56-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-(1,1-dimethylethyl)-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-57-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-5,7,7-trimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-58-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-63-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-hydroxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-64-1 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-6-(trifluoromethyl)- (CA INDEX NAME)




RN 864386-76-5 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-77-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-78-7 CAPLUS


CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-propyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-79-8 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-(phenylmethyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-80-1 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)




RN 864386-81-2 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-82-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-ethyl-5,6,7,8-tetrahydro-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-83-4 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]-3-(phenylmethyl)- (CA INDEX NAME)




RN 864386-84-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro-3-methyl- (CA INDEX NAME)



RN 864386-85-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-3-ethyl-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-86-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)

10/513699




RN 864386-87-8 CAPLUS

CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3,6-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-88-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-5,6,7,8-tetrahydro-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-89-0 CAPLUS


CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-90-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-(1-methylethyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME).

10/513699





RN 864386-91-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-92-5 CAPLUS


CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-93-6 CAPLUS


CN 4(3H)-Quinazolinone, 5-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-95-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-
(CA INDEX NAME)




RN 864386-96-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-
(CA INDEX NAME)



RN 864386-97-0 CAPLUS


CN 4(3H)-Quinazolinone, 6,7-dimethoxy-3-methyl-2-[4-[4-(2-quinolinyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-99-2 CAPLUS


CN 4(3H)-Quinazolinone, 3,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-
piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864387-00-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864387-01-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




IT 864387-19-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864387-19-9 CAPLUS

CN Pyrido[4,3-d]pyrimidine-6(4H)-carboxylic acid, 3-amino-3,5,7,8-tetrahydro-4-oxo-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:465983 CAPLUS

DOCUMENT NUMBER: 137:47214

TITLE: Preparation of 2-substituted-4(3H)-quinazolinone derivatives as PARP inhibitors

INVENTOR(S): Matsuoka, Nobuya; Iwashita, Akinori; Yamazaki, Shunji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kamijo, Kazunori; Nakanishi, Isao; Hattori, Kouji; Kido, Yoshiyuki; Ishida, Junya; Yamamoto, Hirofumi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048117	A1	20020620	WO 2001-JP10601	20011205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2431406	A1	20020620	CA 2001-2431406	20011205
AU 2002021047	A5	20020624	AU 2002-21047	20011205
EP 1355888	A1	20031029	EP 2001-270531	20011205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515544	T	20040527	JP 2002-549648	20011205
US 2004077667	A1	20040422	US 2003-433947	20030609
PRIORITY APPLN. INFO.:			AU 2000-2016	A 20001211
			WO 2001-JP10601	W 20011205

OTHER SOURCE(S): MARPAT 137:47214

GI



AB Title compds. I [R1 = (un)substituted cyclic amino group(s); R2 = substituent; n = 0-4; L = alkylene, alkenylene] were prepared For instance, 2-amino-6-chlorobenzamide was coupled to 4-pentenoyl chloride (THF, i-PrNEt₂, 5°C, 30 min) and the product treated with 1N NaOH to afford 2-(3-butenyl)-5-chloro-4(3H)-quinazolinone. This intermediate was oxidatively cleaved (dioxane, OsO₄, t-BuOH; NaIO₄) effecting cyclization to 8-chloro-1-hydroxy-2,3-dihydropyrrolo[2,1-b]quinazoline-9(1H)-one isolated as a colorless powder. This was used to alkylate 1,2,3,6-tetrahydro-4-phenylpyridine (CH₃CNaq, HOAc, NaCNBH₃) to afford II. Selected compds. of the invention had IC₅₀ < 0.5 μM for poly(ADP-ribose)polymerase (PARP). I are useful for the treatment of NMDA- and NO-induced toxicity, tissue damage resulting from apoptosis, etc.


IT 437997-62-1P 437997-63-2P 437997-64-3P
437997-65-4P 437997-66-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of 2-[ω-substituted(hetero)aryl-alkyl]substituted-4(3H)-quinazolinone derivs.)

RN 437997-62-1 CAPLUS


CN 4(1H)-Quinazolinone, 2-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]- (9CI)
(CA INDEX NAME)




RN 437997-63-2 CAPLUS

CN 4(1H)-Quinazolinone, 8-chloro-2-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]- (9CI)
(CA INDEX NAME)


10/513699




RN 437997-64-3 CAPLUS
CN 4(1H)-Quinazolinone, 2-[3-[4-(4-pyridinyl)-1-piperazinyl]propyl]- (9CI)
(CA INDEX NAME)



RN 437997-65-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-chloro-2-[3-[4-(4-pyridinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 437997-66-5 CAPLUS
CN 4(1H)-Quinazolinone, 2-[3-(4-pyrazinyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.33

201.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

FILE 'REGISTRY' ENTERED AT 14:20:22 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707piperidine.str


L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

10/513699



G1 H, NH2, Cb, Ak.

G2 C, H, Ak

G3 C, N

Structure attributes must be viewed using STN Express query preparation.

=> s l4 full

FULL SEARCH INITIATED 14:20:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1996 TO ITERATE

100.0% PROCESSED 1996 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

373.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.34

FILE 'CAPLUS' ENTERED AT 14:20:55 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996); unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

<12/04/2007>

Erich Leese

10/513699

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d ibib abs hitstr

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

10/513699

SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.

ENTER DISPLAY FORMAT (IDE):.

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 864386-38-9 REGISTRY


ED Entered STN: 03 Oct 2005

CN Pyrido[4,3-d]pyrimidin-4(3H)-one, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

MF C24 H31 N7 O

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 14 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 14:21:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1996 TO ITERATE

100.0% PROCESSED 1996 ITERATIONS

SEARCH TIME: 00.00.01

1 ANSWERS

L6

1 SEA SSS FUL L4

<12/04/2007>

Erich Leese

10/513699

L7 1 L6

=> s 17 full

L8 1 L6

=> d ibib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:979639 CAPLUS

DOCUMENT NUMBER: 143:286443

TITLE: Preparation of pyrimidine derivatives as 5-HT3
receptor antagonists having agonistic activity on
5-HT1A

INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira;
Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru;
Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto,
Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan

SOURCE: PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005217320	A1	20050909	AU 2005-217320	20050225
CA 2557541	A1	20050909	CA 2005-2557541	20050225
EP 1724267	A1	20061122	EP 2005-719969	20050225
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1922171	A	20070228	CN 2005-80005603	20050225
US 2007197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040	A 20040226
			JP 2004-322858	A 20041105
			WO 2005-JP3691	W 20050225

OTHER SOURCE(S): MARPAT 143:286443

GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

4.24	553.12
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.78	-3.12
-------	-------

FILE 'REGISTRY' ENTERED AT 14:23:13 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when

10/513699

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707ix.str


L9 STRUCTURE UPLOADED

=>

=> d 19

L9 HAS NO ANSWERS

L9 STR



G1 H, NH2, Cb, Ak

G2 C, H, Ak

G3 C, N

Structure attributes must be viewed using STN Express query preparation.

=> s 19 full

FULL SEARCH INITIATED 14:40:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 218 TO ITERATE

100.0% PROCESSED 218 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L10 2 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.15

738.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.12

<12/04/2007>

Erich Leese

10/513699

FILE 'CAPLUS' ENTERED AT 14:40:56 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)



Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l10 full
L11 1 L10

=> d abs bib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared For example, treatment of potassium

10/513699

3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A}

IN Sato, Michitaka; Matsui, Teruaki; Asagarsu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
/	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005217320	A1	20050909	AU 2005-217320	20050225
	CA 2557541	A1	20050909	CA 2005-2557541	20050225
	EP 1724267	A1	20061122	EP 2005-719969	20050225
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 1922171	A	20070228	CN 2005-80005603	20050225
	US 2007197551	A1	20070823	US 2006-590707	20060825
PRAI	JP 2004-52040	A	20040226		
	JP 2004-322858	A	20041105		
	WO 2005-JP3691	W	20050225		

OS MARPAT 143:286443

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.24

742.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-3.90

FILE 'REGISTRY' ENTERED AT 14:42:41 ON 19 SEP 2007

<12/04/2007>

Erich Leese

10/513699

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707x.str

L12 STRUCTURE UPLOADED

=> s l12 full

FULL SEARCH INITIATED 14:43:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 585 TO ITERATE

100.0% PROCESSED 585 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L13 0 SEA SSS FUL L12

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	173.90	916.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'REGISTRY' ENTERED AT 14:45:23 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details:

<12/04/2007>

Erich Leese

10/513699

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707v.str

L14 STRUCTURE UPLOADED

=> s l14 full

FULL SEARCH INITIATED 14:46:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 930 TO ITERATE

100.0% PROCESSED 930 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L15 1 SEA SSS FUL L14

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

1088.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.90

FILE 'CAPLUS' ENTERED AT 14:46:34 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

<12/04/2007>

Erich Leese



10/513699

=> s l15 full

L16 . 1 L15

=> d abs bib

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A}

IN Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			

10/513699

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005217320 A1 20050909 AU 2005-217320 20050225

CA 2557541 A1 20050909 CA 2005-2557541 20050225

EP 1724267 A1 20061122 EP 2005-719969 20050225

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1922171 A 20070228 CN 2005-80005603 20050225

US 2007197551 A1 20070823 US 2006-590707 20060825

PRAI JP 2004-52040 A 20040226

JP 2004-322858 A 20041105

WO 2005-JP3691 W 20050225

OS MARPAT 143:286443

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.24	1093.20

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-4.68

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 14:48:16 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707xii.str

<12/04/2007>

Erich Leese

10/513699

L17 STRUCTURE UPLOADED

=> s l17 full

FULL SEARCH INITIATED 14:49:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L18 4 SEA SSS FUL L17

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

1265.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-4.68

FILE 'CAPLUS' ENTERED AT 14:49:15 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s l18 full

L19 1 L18

=> d abs bib

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A}

IN Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005217320	A1	20050909	AU 2005-217320	20050225
	CA 2557541	A1	20050909	CA 2005-2557541	20050225

10/513699

EP 1724267 A1 20061122 EP 2005-719969 20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1922171 A 20070228 CN 2005-80005603 20050225
US 2007197551 A1 20070823 US 2006-590707 20060825
PRAI JP 2004-52040 A 20040226
JP 2004-322858 A 20041105
WO 2005-JP3691 W 20050225
OS MARPAT 143:286443
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.18	1270.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.78	-5.46

FILE 'REGISTRY' ENTERED AT 14:52:15 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707xi.str

L20 STRUCTURE UPLOADED

=>

s l20 full
FULL SEARCH INITIATED 14:52:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

<12/04/2007>

Erich Leese

10/513699

L21 0 SEA SSS FUL L20

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.90	1444.83

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-5.46

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 14:55:00 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707xv.str

L22 STRUCTURE UPLOADED

=> s l22 full

FULL SEARCH INITIATED 14:55:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L23 0 SEA SSS FUL L22

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.90	1618.73

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-5.46

CA SUBSCRIBER PRICE

<12/04/2007>

Erich Leese

10/513699

FILE 'REGISTRY' ENTERED AT 14:58:05 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707vii.str

L24 STRUCTURE UPLOADED

=> s l24 full

FULL SEARCH INITIATED 14:58:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 145 TO ITERATE

100.0% PROCESSED 145 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L25 10 SEA SSS FULL L24

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	172.10	1790.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-5.46

FILE 'CAPLUS' ENTERED AT 14:58:34 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the

10/513699

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:



<http://www.cas.org/infopolicy.html>

=> s l25 full

L26 1 L25

=> d abs bib

L26 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A}

IN Sato, Michitaka; Matsui, Teruaki; Asagarsu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

10/513699

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005217320	A1	20050909	AU 2005-217320	20050225
	CA 2557541	A1	20050909	CA 2005-2557541	20050225
	EP 1724267	A1	20061122	EP 2005-719969	20050225
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1922171	A	20070228	CN 2005-80005603	20050225
	US 2007197551	A1	20070823	US 2006-590707	20060825
PRAI	JP 2004-52040	A	20040226		
	JP 2004-322858	A	20041105		
	WO 2005-JP3691	W	20050225		

OS MARPAT 143:286443

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.77	1794.60

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-6.24

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 15:00:01 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

<12/04/2007>

Erich Leese

10/513699

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.05	1798.65

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-6.24

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 15:05:30 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707vi.str

L27 STRUCTURE UPLOADED

=> s l27 full

FULL SEARCH INITIATED 15:06:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 244 TO ITERATE

100.0% PROCESSED 244 ITERATIONS
SEARCH TIME: 00.00.01

15 ANSWERS

L28 15 SEA SSS FUL L27

=> file caplus

<12/04/2007>

Erich Leese

10/513699

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

1971.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-6.24

FILE 'CAPLUS' ENTERED AT 15:06:55 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



=> s 128 full

L29 1 L28

=> d abs bib

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

GI



<12/04/2007>

Erich Leese

AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT3 receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 · CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A

IN Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI.	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005217320	A1	20050909	AU 2005-217320	20050225
	CA 2557541	A1	20050909	CA 2005-2557541	20050225
	EP 1724267	A1	20061122	EP 2005-719969	20050225
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1922171	A	20070228	CN 2005-80005603	20050225
	US 2007197551	A1	20070823	US 2006-590707	20060825
PRAI	JP 2004-52040	A	20040226		
	JP 2004-322858	A	20041105		
	WO 2005-JP3691	W	20050225		

OS MARPAT 143:286443

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.24	1975.44

FULL ESTIMATED COST

10/513699

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-7.02

FILE 'REGISTRY' ENTERED AT 15:08:52 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10590707xiv.str

L30 STRUCTURE UPLOADED

=> s l30 full

FULL SEARCH INITIATED 15:09:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 246 TO ITERATE

100.0% PROCESSED	246 ITERATIONS	3 ANSWERS
SEARCH TIME: 00.00.01		

L31 3 SEA SSS FUL L30

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	2147.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'CAPLUS' ENTERED AT 15:09:53 ON 19 SEP 2007.
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

<12/04/2007>

Erich Leese

10/513699

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l31 full
L32 0 L31

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	1.88	2149.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'REGISTRY' ENTERED AT 15:12:26 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10590707xiii.str

L33 STRUCTURE UPLOADED

<12/04/2007>

Erich Leese

10/513699

=> s l33 full

FULL SEARCH INITIATED 15:13:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 242 TO ITERATE

100.0% PROCESSED 242 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L34 0 SEA SSS FUL L33

=>

Uploading C:\Program Files\Stnexp\Queries\10590707iv.str

L35 STRUCTURE UPLOADED

=> s l35 full

FULL SEARCH INITIATED 15:18:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5952 TO ITERATE

100.0% PROCESSED 5952 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L36 0 SEA SSS FUL L35

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

348.70

2498.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.02

FILE 'REGISTRY' ENTERED AT 15:19:47 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

<12/04/2007>

Erich Leese

10/513699

Uploading C:\Program Files\Stnexp\Queries\10590707iii.str

L37 STRUCTURE UPLOADED

=> s l37 full

FULL SEARCH INITIATED 15:20:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 163 TO ITERATE

100.0% PROCESSED 163 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L38 1 SEA SSS FUL L37

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

2670.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.02

FILE 'CAPLUS' ENTERED AT 15:20:38 ON 19 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



=> s l38 full

L39 1 L38

=> d abs bib

L39 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

AN 2005:979639 CAPLUS

DN 143:286443

TI Preparation of pyrimidine derivatives as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A}

IN Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PA Teikoku Hormone Mfg. Co., Ltd., Japan

SO PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW; AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005217320	A1	20050909	AU 2005-217320	20050225
	CA 2557541	A1	20050909	CA 2005-2557541	20050225

10/513699

EP 1724267 A1 20061122 EP 2005-719969 20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1922171 A 20070228 CN 2005-80005603 20050225
US 2007197551 A1 20070823 US 2006-590707 20060825
PRAI JP 2004-52040 A 20040226
JP 2004-322858 A 20041105
WO 2005-JP3691 W 20050225
OS MARPAT 143:286443
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.88	2680.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.78	-7.80

FILE 'REGISTRY' ENTERED AT 15:29:44 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10590707i.str

L40 STRUCTURE UPLOADED

=> s l40 full
FULL SEARCH INITIATED 15:30:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6029 TO ITERATE

100.0% PROCESSED 6029 ITERATIONS 105 ANSWERS
SEARCH TIME: 00.00.01

<12/04/2007>

Erich Leese

10/513699

L41 105 SEA SSS FUL L40

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	2852.65

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.80

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 15:30:31 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007 (20070918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l41 full
L42 3 L41

=> d ibib abs hitstr tot

L42 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:729635 CAPLUS
DOCUMENT NUMBER: 147:72778
TITLE: Preparation of quinazolinone derivatives and related analogs as antiproliferative agents
INVENTOR(S): Bergnes, Gustave
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004018058	A2	20040304	WO 2003-US26093	20030820
WO 2004018058	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003262747 A1 20040311 AU 2003-262747 20030820
 EP 1539180 A2 20050615 EP 2003-793179 20030820
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005536553 T 20051202 JP 2004-531141 20030820
 PRIORITY APPLN. INFO.: US 2002-404864P P 20020821
 WO 2003-US26093 W 20030820
 OTHER SOURCE(S): MARPAT 147:72778
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-4 independently = H, OH, (un)substituted alkyl, etc.;
 R5 = H, (un)substituted alkyl, aryl, or aralkyl; R6 and R9 independently =
 H, (un)substituted alkyl, aryl, etc.; R7 = (un)substituted alkyl, aryl or
 aralkyl; R8 = H, (un)substituted alkyl, aryl or aralkyl; n = 1 or 2], and
 their pharmaceutically acceptable salts, are prepared and disclosed as
 antiproliferative agents by modulation of KSP (a mitotic kinesin)
 activity. Thus, e.g., II was prepared by substitution of
 3-benzyl-2-(1-bromopropyl)-7-chloro-3H-quinazolin-4-one with
 3-p-tolylpiperazine-1-carboxylic acid tert-Bu ester. Bioassays are
 described and the compds. of the invention were stated to show activity.


IT 941712-02-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of quinazolinone derivs. and related analogs as antiproliferative
 agents)

RN 941712-02-3 CAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-[1-[4-[4-(1-methylethyl)-2-pyridinyl]-1-
 piperazinyl]propyl]-3-(phenylmethyl)- (CA INDEX NAME)



L42 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:979639 CAPLUS
 DOCUMENT NUMBER: 143:286443

10/513699

TITLE: Preparation of pyrimidine derivatives as 5-HT3
receptor antagonists having agonistic activity on
5-HT1A

INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira;
Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru;
Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto,
Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan

SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005217320	A1	20050909	AU 2005-217320	20050225
CA 2557541	A1	20050909	CA 2005-2557541	20050225
EP 1724267	A1	20061122	EP 2005-719969	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1922171	A	20070228	CN 2005-80005603	20050225
US 2007197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040	A 20040226
			JP 2004-322858	A 20041105
			WO 2005-JP3691	W 20050225
OTHER SOURCE(S):		MARPAT 143:286443		
GI				



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-yl)piperazin-1-yl]propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

IT 864385-97-7P 864385-98-8P 864386-03-8P
 864386-04-9P 864386-05-0P 864386-07-2P
 864386-09-4P 864386-10-7P 864386-11-8P
 864386-13-0P 864386-14-1P 864386-15-2P
 864386-16-3P 864386-18-5P 864386-19-6P
 864386-21-0P 864386-23-2P 864386-28-7P
 864386-34-5P 864386-35-6P 864386-45-8P
 864386-46-9P 864386-47-0P 864386-49-2P
 864386-50-5P 864386-90-3P 864386-91-4P
 864386-92-5P 864386-93-6P 864386-95-8P
 864386-96-9P 864386-97-0P 864386-99-2P
 864387-00-8P 864387-01-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)

RN 864385-97-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-
 (CA INDEX NAME)

10/513699




RN 864385-98-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-03-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(3,4-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-04-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2,3-dihydro-1H-cyclopenta[c]quinolin-4-yl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-05-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(7,8,9,10-tetrahydro-6-phenanthridinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-07-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-(4-pyrrolo[1,2-a]quinoxalin-4-yl-1-piperazinyl)butyl]- (CA INDEX NAME)



RN 864386-09-4 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-7-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-10-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-6-bromo-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-11-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6,7,8-trimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-13-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-14-1 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-15-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-16-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(5-methoxy-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-18-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-8-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-19-6 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-5-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-21-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-8-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)

10/513699




RN 864386-23-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-7-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-28-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4,8-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-34-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-8-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-35-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6,7-dimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)


10/513699

piperazinyl]butyl] - (CA INDEX NAME)




RN 864386-45-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (CA INDEX NAME)




RN 864386-46-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl] - (CA INDEX NAME)



RN 864386-47-0 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-7-(trifluoromethyl) - (CA INDEX NAME)



RN 864386-49-2 CAPLUS


10/513699

CN 4(3H)-Quinazolinone, 3-amino-6-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-50-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-7-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-90-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-(1-methylethyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-91-4 CAPLUS



CN 4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



10/513699


RN 864386-92-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-methoxyphenyl)-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-93-6 CAPLUS

CN 4(3H)-Quinazolinone, 5-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-95-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-96-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-ethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




10/513699




RN 864386-97-0 CAPLUS

CN 4(3H)-Quinazolinone, 6,7-dimethoxy-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864386-99-2 CAPLUS

CN 4(3H)-Quinazolinone, 3,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




RN 864387-00-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864387-01-9 CAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:465983 CAPLUS

DOCUMENT NUMBER: 137:47214

TITLE: Preparation of 2-substituted-4(3H)-quinazolinone derivatives as PARP inhibitors

INVENTOR(S): Matsuoka, Nobuya; Iwashita, Akinori; Yamazaki, Shunji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kamiyo, Kazunori; Nakanishi, Isao; Hattori, Kouji; Kido, Yoshiyuki; Ishida, Junya; Yamamoto, Hirofumi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048117	A1	20020620	WO 2001-JP10601	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431406	A1	20020620	CA 2001-2431406	20011205
AU 2002021047	A5	20020624	AU 2002-21047	20011205
EP 1355888	A1	20031029	EP 2001-270531	20011205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515544	T	20040527	JP 2002-549648	20011205
US 2004077667	A1	20040422	US 2003-433947	20030609
PRIORITY APPLN. INFO.:			AU 2000-2016	A 20001211
			WO 2001-JP10601	W 20011205

OTHER SOURCE(S): MARPAT 137:47214

GI



AB Title compds. I [R1 = (un)substituted cyclic amino group(s); R2 = substituent; n = 0-4; L = alkylene, alkenylene] were prepared For instance, 2-amino-6-chlorobenzamide was coupled to 4-pentenoyl chloride (THF, i-PrNEt₂, 5°C, 30 min) and the product treated with 1N NaOH to afford 2-(3-butenyl)-5-chloro-4(3H)-quinazolinone. This intermediate was oxidatively cleaved (dioxane, OsO₄, t-BuOH; NaIO₄) effecting cyclization to 8-chloro-1-hydroxy-2,3-dihydropyrrolo[2,1-b]quinazoline-9(1H)-one isolated as a colorless powder. This was used to alkylate 1,2,3,6-tetrahydro-4-phenylpyridine (CH₃CN_{aq}, HOAc, NaCNBH₃) to afford II. Selected compds. of the invention had IC₅₀ < 0.5 μM for poly(ADP-ribose)polymerase (PARP). I are useful for the treatment of NMDA- and NO-induced toxicity, tissue damage resulting from apoptosis, etc.


IT 437997-62-1P 437997-63-2P 437997-64-3P
437997-65-4P 437997-66-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of 2-[ω-substituted(hetero)aryl-alkyl]substituted-4(3H)-quinazolinone derivs.)

RN 437997-62-1 CAPLUS


CN 4(1H)-Quinazolinone, 2-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl] - (9CI)
(CA INDEX NAME)




RN 437997-63-2 CAPLUS

CN 4(1H)-Quinazolinone, 8-chloro-2-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl] - (9CI)
(CA INDEX NAME)


10/513699




RN 437997-64-3 CAPLUS
CN 4(1H)-Quinazolinone, 2-[3-[4-(4-pyridinyl)-1-piperazinyl]propyl] - (9CI)
(CA INDEX NAME)



RN 437997-65-4 CAPLUS
CN 4(1H)-Quinazolinone, 8-chloro-2-[3-[4-(4-pyridinyl)-1-piperazinyl]propyl] - (9CI)
(CA INDEX NAME)



RN 437997-66-5 CAPLUS
CN 4(1H)-Quinazolinone, 2-[3-(4-pyrazinyl-1-piperazinyl)propyl] - (9CI) (CA
INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>

Erich Leese

10/513699

=> d his

(FILE 'HOME' ENTERED AT 13:54:18 ON 19 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:09:32 ON 19 SEP 2007

L1 STRUCTURE UPLOADED
L2 152 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:10:41 ON 19 SEP 2007

L3 3 S L2 FULL

FILE 'REGISTRY' ENTERED AT 14:20:22 ON 19 SEP 2007

L4 STRUCTURE UPLOADED
L5 1 S L4 FULL

FILE 'CAPLUS' ENTERED AT 14:20:55 ON 19 SEP 2007

FILE 'REGISTRY' ENTERED AT 14:21:14 ON 19 SEP 2007

FILE 'CAPLUS' ENTERED AT 14:21:19 ON 19 SEP 2007
S L4

FILE 'REGISTRY' ENTERED AT 14:21:32 ON 19 SEP 2007

L6 1 S L4 FULL

FILE 'CAPLUS' ENTERED AT 14:21:32 ON 19 SEP 2007

L7 1 S L6 FULL
L8 1 S L7 FULL

FILE 'REGISTRY' ENTERED AT 14:23:13 ON 19 SEP 2007

L9 STRUCTURE UPLOADED
L10 2 S L9 FULL

FILE 'CAPLUS' ENTERED AT 14:40:56 ON 19 SEP 2007

L11 1 S L10 FULL

FILE 'REGISTRY' ENTERED AT 14:42:41 ON 19 SEP 2007

L12 STRUCTURE UPLOADED
L13 0 S L12 FULL

FILE 'REGISTRY' ENTERED AT 14:45:23 ON 19 SEP 2007

L14 STRUCTURE UPLOADED
L15 1 S L14 FULL

FILE 'CAPLUS' ENTERED AT 14:46:34 ON 19 SEP 2007

L16 1 S L15 FULL

FILE 'REGISTRY' ENTERED AT 14:48:16 ON 19 SEP 2007

L17 STRUCTURE UPLOADED
L18 4 S L17 FULL

FILE 'CAPLUS' ENTERED AT 14:49:15 ON 19 SEP 2007

L19 1 S L18 FULL

FILE 'REGISTRY' ENTERED AT 14:52:15 ON 19 SEP 2007

L20 STRUCTURE UPLOADED
L21 0 S L20 FULL

<12/04/2007>

Erich Leese

10/513699

FILE 'REGISTRY' ENTERED AT 14:55:00 ON 19 SEP 2007
L22 STRUCTURE UPLOADED
L23 0 S L22 FULL

FILE 'REGISTRY' ENTERED AT 14:58:05 ON 19 SEP 2007
L24 STRUCTURE UPLOADED
L25 10 S L24 FULL

FILE 'CAPLUS' ENTERED AT 14:58:34 ON 19 SEP 2007
L26 1 S L25 FULL

FILE 'REGISTRY' ENTERED AT 15:00:01 ON 19 SEP 2007

FILE 'REGISTRY' ENTERED AT 15:05:30 ON 19 SEP 2007
L27 STRUCTURE UPLOADED
L28 15 S L27 FULL

FILE 'CAPLUS' ENTERED AT 15:06:55 ON 19 SEP 2007
L29 1 S L28 FULL

FILE 'REGISTRY' ENTERED AT 15:08:52 ON 19 SEP 2007
L30 STRUCTURE UPLOADED
L31 3 S L30 FULL

FILE 'CAPLUS' ENTERED AT 15:09:53 ON 19 SEP 2007
L32 0 S L31 FULL

FILE 'REGISTRY' ENTERED AT 15:12:26 ON 19 SEP 2007
L33 STRUCTURE UPLOADED
L34 0 S L33 FULL
L35 STRUCTURE UPLOADED
L36 0 S L35 FULL

FILE 'REGISTRY' ENTERED AT 15:19:47 ON 19 SEP 2007
L37 STRUCTURE UPLOADED
L38 1 S L37 FULL

FILE 'CAPLUS' ENTERED AT 15:20:38 ON 19 SEP 2007
L39 1 S L38 FULL

FILE 'REGISTRY' ENTERED AT 15:29:44 ON 19 SEP 2007
L40 STRUCTURE UPLOADED
L41 105 S L40 FULL

FILE 'CAPLUS' ENTERED AT 15:30:31 ON 19 SEP 2007
L42 3 S L41 FULL